Advances in the Detection of Pancreatic Cancer Through Liquid Biopsy

Yan, T.; Huang, Jiaqi; Huang, Shiyun; Ahir, Bhavesh K.; Li, Long-Man; Zhong, Jian‐Hong

doi:10.3389/fonc.2021.801173

Cited by 6 publications

(3 citation statements)

References 97 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of recent studies have demonstrated the potential of liquid biopsy for cancer screening, refinement of diagnosis, and early of cancer recurrences [43,61]. By detecting circulating tumor cells, nucleic acids, and exosomes, the method can be used for early cancer detection, diagnosis, and prognosis in various types of cancer [35,63,71,149]. Additionally, liquid biopsy can provide insights into cancer progression and treatment response by assessing cancer cachexia, muscle-derived microRNAs, and energy metabolism [16].…”

Section: Early Detection and Diagnosismentioning

confidence: 99%

Liquid Biopsy in the Clinical Management of Cancers

Yin,

See,

Ming

et al. 2024

Preprint

View full text Add to dashboard Cite

Liquid biopsy, a non-invasive diagnosis that examines circulating tumor components in body fluids, is increasingly used in cancer management. An overview of relevant literature emphasizes the current state of liquid biopsy applications in cancer care. Liquid biopsy, particularly circulating tumor DNA (ctDNA), circulating tumor RNAs (ctRNA), circulating tumor cells (CTCs), extracellular vesicles, and other cell-free nucleic acids, offers promising opportunities for early cancer diagnosis, treatment selection, monitoring, and disease assessment. The implementation of liquid biopsy in precision medicine has shown significant potential in various cancer types, including lung cancer, colorectal cancer, breast cancer, and prostate cancer. Advances in genomic and molecular technologies, such as next generation sequencing (NGS) and digital polymerase chain reaction (dPCR) have expanded the utility of liquid biopsy, enabling the detection of somatic variants and actionable genomic alterations in tumors. Liquid biopsy has also demonstrated utility in predicting treatment responses, monitoring minimal residual disease (MRD), and assessing tumor heterogeneity. Nevertheless, standardizing liquid biopsy techniques, interpreting results, and integrating them into clinical routine remain challenges. Despite these challenges, liquid biopsy has significant clinical implications in cancer management, offering a dynamic and non-invasive approach to understanding tumor biology and guiding personalized treatment strategies.

show abstract

Section: Early Detection and Diagnosismentioning

confidence: 99%

Liquid Biopsy in the Clinical Management of Cancers

Yin,

See,

Ming

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…miRNAs are noncoding, single-stranded RNA molecules up to 22 nucleotides long that function as posttranscriptional gene expression regulators [40]. Various miRNAs have been utilized to differentiate PDAC patients from those with benign lesions, CP, and healthy controls, and a JAMA-published study reported 38 significantly dysregulated miRNAs in PDAC patients compared to controls [41].…”

Section: Mirnasmentioning

confidence: 99%

Clinical Application of Liquid Biopsy in Pancreatic Cancer: A Narrative Review

Ramírez-Maldonado,

López Gordo,

Major Branco

et al. 2024

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma contributes significantly to global cancer-related deaths, featuring only a 10% survival rate over five years. The quest for novel tumor markers is critical to facilitate early diagnosis and tailor treatment strategies for this disease, which is key to improving patient outcomes. In pancreatic ductal adenocarcinoma, these markers have been demonstrated to play a crucial role in early identification, continuous monitoring, and prediction of its prognosis and have led to better patient outcomes. Nowadays, biopsy specimens serve to ascertain diagnosis and determine tumor type. However, liquid biopsies present distinct advantages over conventional biopsy techniques. They offer a noninvasive, easily administered procedure, delivering insights into the tumor’s status and facilitating real-time monitoring. Liquid biopsies encompass a variety of elements, such as circulating tumor cells, circulating tumor DNA, extracellular vesicles, microRNAs, circulating RNA, tumor platelets, and tumor endothelial cells. This review aims to provide an overview of the clinical applications of liquid biopsy as a technique in the management of pancreatic cancer.

show abstract

“…Life 2022, 12, 327 2 of 16 Recently, advances have been made to detect metastatic pancreatic ductal adenocarcinoma (PDAC) using molecular magnetic resonance imaging (MMRI) [14]. Additionally, advances have been made in liquid biopsy [15] and in finding specific biomolecular or subcellular targets [16][17][18][19], new therapeutic agents [20], and nanomedicine applications [21][22][23][24][25][26][27][28]. Moreover, our understanding of the molecular biology events of pancreatic cancer cells has increased [29][30][31].…”

Section: Introductionmentioning

confidence: 99%

A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer

González

López

Lomelí

et al. 2022

Life

View full text Add to dashboard Cite

Pancreatic cancer has one of the highest mortality rates among cancers, and a combination of nab-paclitaxel with gemcitabine remains the cornerstone of first-line therapy. However, major advances are required to achieve improvements in patient outcomes. For this reason, several research groups have proposed supplementing treatment with other therapeutic agents. Ongoing studies are being conducted to find the optimal treatment in a first-line setting. In this work, we used a search strategy to compare studies on the efficacy and safety of nab-paclitaxel with gemcitabine in combination with other therapeutic agents based on the criteria of the Preferred Reporting Items for Systematic Reviews. We found seven studies in different clinical phases that met the inclusion criteria. The seven therapeutic agents were ibrutinib, necuparanib, tarextumab, apatorsen, cisplatin, enzalutamide, and momelotinib. Although these therapeutic agents have different mechanisms of action, and molecular biology studies are still needed, the present review was aimed to answer the following question: which formulations of the nab-paclitaxel/gemcitabine regimen in combination with other therapeutic agents are safest for patients with previously untreated metastatic pancreas ductal adenocarcinoma? The triple regimen is emerging as the first-line option for patients with pancreatic cancer, albeit with some limitations. Thus, further studies of this regimen are recommended.

show abstract

Advances in the Detection of Pancreatic Cancer Through Liquid Biopsy

Cited by 6 publications

References 97 publications

Liquid Biopsy in the Clinical Management of Cancers

Liquid Biopsy in the Clinical Management of Cancers

Clinical Application of Liquid Biopsy in Pancreatic Cancer: A Narrative Review

A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer

Contact Info

Product

Resources

About